fregime
TODAYSTOCKSARCHIVEABOUTGUIDE
Sign inFollow your stocks

Write what you believe about your stocks; every morning the cited record grades it: supported, challenged, or untouched. Never opinions.

Development · 29 Oct 2026

HYUNDAI, full dossier

Hyundai Motor India expects sport utility vehicles (SUVs) to account for as much as 75% of its domestic passenger vehicle sales over the next 12-18 months.

1 publisher has reported this development. Each act of reporting is below, cited.

The record

Hyundai Motor India expects sport utility vehicles (SUVs) to account for as much as 75% of its domestic passenger vehicle sales over the next 12-18 months.

autocarpro.in28 Oct 2026

A single act of reporting so far, corroborating sources join this record as they publish.

Hyundai Motor India

₹1,866.90

▲ +0.30%

Close (EOD), as of 28 Oct 2026 · source

Hyundai Motor India: results, dividends, orders, the full cited record →

More on Hyundai Motor India

Hyundai Motor India reported a 23.9% year-on-year decline in consolidated net profit to ₹1,196.2 crore in the second quarter of FY27, even as revenue from operations rose 18.5% to ₹20,696.1 crore.

29 Oct 2026 · 7 publishers

Hyundai Motor India Ltd's revenue crossed ₹20,000 crore for the first time in the September quarter.

29 Oct 2026 · 1 publisher

Adani Enterprises, Hyundai Motor India, Hero MotoCorp, Meesho and Vedanta are among the key companies announcing Q2 FY27 results today.

28 Oct 2026 · 1 publisher

Hyundai Motor India is reporting its September quarter earnings on October 28, 2026.

28 Oct 2026 · 1 publisher

Hyundai Motor India is expected to report healthy revenue growth in the second quarter of FY27, supported by higher volumes, price hikes and a favourable product mix.

28 Oct 2026 · 1 publisher

Every claim carries its citation

This page is the corroborated record of one development: what each credible source reported, linked and dated. We compile and cite; we do not opine.

New here? The reader's guide explains every page, plate by plate.

fregime is informational research software. Content on this page is factual reporting compiled from cited public sources; nothing here is advice, and nothing here expresses an opinion on any security. fregime is not registered with SEBI as an investment adviser or research analyst. Before making investment decisions, consult a SEBI-registered adviser. Price figures are delayed end-of-day values cited to the exchange's published file, never live quotes.